Nautilus Biotechnology

Nautilus Biotechnology, Inc. operates as a life sciences company. The firm develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nautilus Biotechnology reports strong financials and strategic collaborations

Nautilus Biotechnology is strategically positioned with strong financials and key collaborations for future growth.
The company's focus on innovation and customer engagement sets the stage for a successful commercial launch in mid-2024.
Despite challenges like increasing expenses and supply chain issues, Nautilus is poised to capitalize on market opportunities.
CEO's vision of a highly differentiated product and market evolution aligns with the company's strategic direction.

Nautilus Biotechnology advances towards proteome access, strong financial position

Nautilus Biotechnology's Q1 2023 performance reflects strong advancements in its scientific and engineering objectives, positioning the company well for its upcoming platform launch in mid-2024. With a robust financial position and a focus on strategic investments, Nautilus is poised for long-term growth and innovation in the proteomics market.

Nautilus Biotechnology advances in proteomics with strong financial backing

Nautilus Biotechnology's Q2 performance reflects steady progress towards developing a groundbreaking proteomic platform, supported by active industry engagement and a strong financial position.
While facing challenges in managing operating expenses and executing on its technological vision, the company's strategic strengths and opportunities position it for future success.
With a clear focus on innovation and customer value, Nautilus is well-equipped to drive growth, deliver on its promises, and shape the future of proteomics.

Nautilus Biotechnology progresses in Q3, eyes market revolution and growth

Nautilus Biotechnology's Q3 performance reflects advancements in R&D, financial stability, and strategic partnerships.
The company's strengths lie in its innovative platform, expert team, and confidence in value proposition.
Challenges include competitive positioning, operational hurdles, and managing expenses effectively.
Opportunities for Nautilus Biotechnology include industry engagements, market penetration, and sustainable growth.

Nautilus Biotechnology advances Proteome Analysis Platform launch to 2025

Nautilus Biotechnology made progress in 2023 towards launching the Proteome Analysis Platform in 2025, despite a net loss of $17.0 million in Q4. The company's focus on scalability, reproducibility, and collaborations with key partners positions it well for future growth. Challenges in refining the platform's quality and milestones in protein decoding are being addressed to maximize long-term value.

Nautilus Biotechnology excels in proteomics, faces inquiries and growth

Nautilus Biotechnology demonstrated strong performance in proteomic data analysis and platform development in Q1 2024.
While facing challenges in addressing analyst inquiries and managing financial aspects, the company remains well-positioned.
Opportunities lie in leveraging positive feedback, advancing platform development, and engaging in global events for growth.

Nautilus Biotechnology progresses towards commercial launch amidst financial stability

Nautilus Biotechnology demonstrated strong performance and financial stability in Q2 2024, positioning itself for future growth and commercial success.
The company's focus on proteoforms, technological advancements, and strategic leadership are key strengths driving its competitive edge.
Challenges in meeting timelines, managing costs, securing funding, and navigating market competition require strategic focus and execution.
Opportunities in the growing proteomics market, technology advancements, partnerships, and market expansion offer avenues for future growth and success.

Nautilus Biotechnology reports robust Q3 performance and eyes market expansion

Nautilus Biotechnology's Q3 2024 earnings call highlighted strong financial performance, platform development progress, and strategic leadership appointments.
The company's focus on efficient cash management, extended cash runway, and future growth plans underscore a commitment to long-term success.
While facing challenges in probe development and commercialization, Nautilus Biotechnology is well-positioned to capitalize on opportunities in partnerships and market expansion.
Overall, Nautilus Biotechnology's emphasis on innovation, financial prudence, and market engagement sets a positive trajectory for future growth and industry impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.

Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Operator Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tycho Peterson - Jefferies Dan Brennan - TD Cowen Operator Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024.

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024.

Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024

Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call.

Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference.

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics Society award recognizes Dr. Mallick's decades of innovative leadership and science advancing the field of computational proteomics

Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome Former Quantapore founder and CEO brings 20 years of proteomics and genomics industry experience to company developing a platform for comprehensively quantifying the proteome

Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023.

Nautilus Biotechnology Reports Third Quarter 2023 Financial Results

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.

Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023

SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:

Nautilus Biotechnology to Participate in Upcoming August Investor Conferences

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Parag Mallick - Co-Founder, Chief Scientist & Director Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dave Delahunt - Goldman Sachs Dan Brennan - Cowen Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.

Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript

SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023.

Nautilus Biotechnology Reports Second Quarter 2023 Financial Results

SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023.

Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:

Nautilus Biotechnology to Participate in Upcoming June Investor Conferences

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023.

News for Nautilus Biotechnology Stock (NAUT)